Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver, Meng; Carbone, David P.

doi:10.21037/tlcr.2017.09.08

Cited by 40 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, tissue biopsy, an invasive and time‐consuming procedure, is often relied upon for confirmation of lung cancer, yet access to tissue samples is often limited due to the anatomical location of the tumors . Further, to understand tumor progression and the initial response to treatment, re‐biopsy is often required; yet, the information obtained is often confounded by heterogeneity among the primary tumor and secondary metastases, thus limiting a clear representation of the disease profile . Taking into account the limitations of using tissue biopsies, cell‐free microRNAs (cf‐miRNAs), cell‐free DNA (cfDNA), cell‐free long non‐coding RNAs (cf‐lncRNAs), and circulating tumor cells (CTC) that can be detected in liquid biopsies may provide a facile approach to obtain information on tissue‐specific histology, stage, and metastatic status of the tumors .…”

Section: Introductionmentioning

confidence: 99%

“…and the initial response to treatment, re-biopsy is often required; yet, the information obtained is often confounded by heterogeneity among the primary tumor and secondary metastases, thus limiting a clear representation of the disease profile. 5,6 Taking into account the limitations of using tissue biopsies, cell-free microR-NAs (cf-miRNAs), 1 cell-free DNA (cfDNA), 7 cell-free long non-coding RNAs (cf-lncRNAs), 8,9 and circulating tumor cells (CTC) 10 that can be detected in liquid biopsies may provide a facile approach to obtain information on tissue-specific histology, stage, and metastatic status of the tumors. 2,3,11 Such an approach would provide a non-invasive, cost-effective procedure that has the potential to improve overall disease management.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Despite the availability of various diagnostic procedures, a tissue biopsy is still indispensable for the routine diagnosis of lung cancer. However, inaccurate diagnoses can occur, leading to inefficient cancer management. In this context, use of circulating microRNAs (miRNAs) may serve as diagnostic tools as liquid biopsies, and as biomarkers to better understand the molecular mechanisms involved in the progression of cancer. We identified miR‐590‐5p as a potential prognostic marker in the progression of non‐small cell lung cancer (NSCLC). We were able to detect this miRNA in blood plasma samples of NSCLC patients through quantitative real‐time PCR. Our data showed an ~7.5‐fold downregulation of miR‐590‐5p in NSCLC patients compared to healthy controls, which correlated with several clinicopathological features. Further, overexpression of miR‐590‐5p led to decreased cell viability, proliferation, colony formation, migration, and invasion potential of lung cancer cells, whereas its knockdown showed the opposite effect. In addition, the levels of several proteins involved in the epithelial‐to‐mesenchymal transition negatively correlated with miR‐590‐5p levels in lung adenocarcinoma cells and tumors of NSCLC patients. Further, dual‐luciferase reporter assays identified STAT3 as a direct target of miR‐590‐5p, which negatively regulated STAT3 activation and its downstream signaling molecules (eg, Cyclin D1, c‐Myc, Vimentin, and β‐catenin) involved in tumorigenesis. Taken together, our study suggests that miR‐590‐5p functions as a tumor suppressor in NSCLC through regulating the STAT3 pathway, and may serve as a useful biomarker for the diagnosis/prognosis of NSCLC, and as a potential therapeutic target for the treatment of NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This calls for the need of more accurate and minimally invasive biomarkers for cancer treatment, which makes the biomarkers from liquid biopsies the most coveted in the field . Blood or urine‐based biomarkers are capable of being collected using minimally invasive procedures, and can be sampled all through the disease course or before and after specific treatments, to monitor disease progression …”

Section: Introductionmentioning

confidence: 99%

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis

2019

View full text Add to dashboard Cite

Background With the recent advances in the understanding of the interaction of the immune system with developing tumor, it has become imperative to consider the immunological parameters for both cancer diagnosis and disease prognosis. Additionally, in the era of emerging immunotherapeutic strategies in cancer, it is very important to follow the treatment outcome and also to predict the correct immunotherapeutic strategy in individual patients. There being enormous heterogeneity among tumors at different sites or between primary and metastatic tumors in the same individual, or interpatient heterogeneity, it is very important to study the tumor‐immune interaction in the tumor microenvironment and beyond. Importantly, molecular tools and markers identified for such studies must be suitable for monitoring in a noninvasive manner. Recent findings Recent studies have shown that the immune checkpoint molecules play a key role in the development and progression of tumors. In‐depth studies of these molecules have led to the development of most of the cancer immunotherapeutic reagents that are currently either in clinical use or under different phases of clinical trials. Interestingly, many of these cell surface molecules undergo alternative splicing to produce soluble isoforms, which can be tracked in the serum of patients. Conclusions Several studies demonstrate that the serum levels of these soluble isoforms could be used as noninvasive markers for cancer diagnosis and disease prognosis or to predict patient response to specific therapeutic strategies.

show abstract

“…Indeed, blood-based biomarkers can capture the molecular diversity of the disease, while the ease of serial testing enables the monitoring of its spatial and temporal progression. 2 Accumulating studies have employed clinical factors such as hypertension history, diabetes history, 3 and hematological biomarkers including hemoglobin (Hb), platelets (PLTs) and white blood cells (WBCs), in the prognostic analysis of lung cancer patients. 4 However, these studies did not reach consensus on cutoff values and biomarkers selection, which may lead to inaccurate conclusions.…”

mentioning

confidence: 99%

A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators

et al. 2020

View full text Add to dashboard Cite

Aims We aimed to establish a nomogram for lung cancer using patients' characteristics and potential hematological biomarkers. Methods Principle component analysis was used to reduce the dimensions of the data, and each component was transformed into categorical variables based on cutoff values obtained using the X‐tile software. Multivariate analysis was used to determine potential prognostic biomarkers. Five components were used in the predictive nomogram. Internal validation of the model was performed by bootstrapping of samples, while external validation was performed on a separate cohort from Shandong Cancer Hospital. The predictive accuracy of the model was measured by concordance index and risk group stratification. Decision curve analysis was performed to evaluate the net benefit of the models. Results One hundred patients in the Discovery group and 111 patients in the Validation group were retrospectively analyzed in this study. Forty‐seven indexes were sorted into eight subgroups. Five components based on cox regression analysis were enrolled into the predictive nomogram. The nomogram prediction of the probability of 3‐ and 5‐year overall survival was in great concordance with the actual observations. Of interest, the nomogram allowed better risk stratification of patients and better accuracy in predicting patients' survival compared with pathological tumor‐node‐metastasis staging system. Conclusion A nomogram was established for prognosis of lung cancer, which can be used for treatment selection and clinical care management.

show abstract

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Cited by 40 publications

References 33 publications

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

Circulating microRNA‐590‐5p functions as a liquid biopsy marker in non‐small cell lung cancer

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis

A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators

Contact Info

Product

Resources

About